LB Pharmaceuticals Reports Q3 GAAP EPS of -$1.79 and Strong Cash Position
LB Pharmaceuticals (LBRX) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) of -$1.79. Despite the quarterly loss, the company maintains a robust liquidity position with $403.8 million in cash, cash equivalents, and short-term investments as of September 30, 2026. The company's management indicates that its current capital reserves are sufficient to fund operations through at least the second quarter of 2029. This extended runway is intended to support the company through multiple upcoming clinical milestones.
Tickers: $LBRX